Jazz Pharmaceuticals Azioni (NASDAQ: JAZZ)

Ultime notizie per Jazz Pharmaceuticals (NASDAQ:JAZZ) Azioni

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

DUBLIN, April 25, 2025 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.
The CHMP's recommendation will now be reviewed by the European Commission which has the authority to approve medicines in all EU Member States, Iceland, Norway, and Liechtenstein, and is expected to make a final decision.
 &nbsp;
 &nbsp;

News

JAZZ

Jazz Pharma Secures CHMP Support for Zanidatamab for Treatment of Advanced HER2-Positive Biliary Tract Cancer

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.0, along with a high estimate of $230.00 and a low estimate of $150.00. Observing a 6.55% increase, the current average has risen from the previous average price target of $182.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311642_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $183.00&#x7C;$175.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $179.00&#x7C;$145.00 &#x7C; 
&#x7C;Gregory Fraser &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$220.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $200.00&#x7C;$190.00 &#x7C; 
&#x7C;Charles Duncan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $176.00&#x7C;$163.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $178.00&#x7C;$179.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $209.00&#x7C;$200.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $210.00&#x7C;$205.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $170.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 7.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.51.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Jazz Pharmaceuticals Stands With Analysts

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $210 price target.

Price Target

Reiteration

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Legal

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays raised Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) price target from $39 to $41. Barclays analyst Matt Miksic maintained an Overweight rating. Baxter International shares closed at $36.57 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BAX/analyst-ratings">view this stock</a>.</li>
<li>Barclays boosted the price target for Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $940 to $980. Barclays analyst Karen Short maintained an Equal-Weight rating. Costco shares closed at $964.31 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised SLM Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) price target from $32 to $38. Morgan Stanley analyst Jeffery Harte maintained an Overweight rating. SLM shares closed at $29.46 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/SLM/analyst-ratings">view this stock</a>.</li>
<li>B of A Securities slashed the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $333 to $318. B of A Securities analyst Joshua Shanker maintained a Buy rating. Progressive shares closed at $279.82 on Friday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from $38 to $32. Baird analyst Andrew Wittmann maintained a Neutral rating. WillScot Holdings shares closed at $28.07 on Friday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) price target from $200 to $217. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Jazz Pharmaceuticals shares settled at $138.81 on Friday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) price target from $13.7 to $29. Citigroup analyst Jeff Chung upgraded the stock from Neutral to Buy. XPeng shares closed at $23.60 on Friday. <a href="https://www.benzinga.com/quote/XPEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) price target from $423 to $380. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. Sherwin-Williams shares closed at $363.62 on Friday.  <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $44 to $51. Benchmark analyst Mike Hickey maintained a Buy rating. DraftKings shares settled at $39.41 on Friday. <a href="https://www.benzinga.com/quote/dkng/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) price target from $165 to $185. Jefferies analyst John Colantuoni upgraded the stock from Hold to Buy. Airbnb shares closed at $134.39 on Friday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Trading Ideas

ABNB

COST

DKNG

XPEV

DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $200 to $217.

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217

Morgan Stanley analyst Jeffrey Hung assumes Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight rating and raises Price Target to $183.

Initiation

Morgan Stanley Assumes Jazz Pharmaceuticals at Overweight, Raises Price Target to $183

UBS analyst Ashwani Verma upgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Neutral to Buy and raises the price target from $145 to $179.

Upgrades

UBS Upgrades Jazz Pharmaceuticals to Buy, Raises Price Target to $179

On Wednesday, Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">consensus loss of 3 cents</a>.
Sales came at $31.03 million, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $45.2 million</a>.
In its fourth-quarter earnings results, Zymeworks said it is increasing its development <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44151625/zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial-result" rel="noreferrer noopener">efforts on plans for ZW251</a>.
&#8220;Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprioritize resources for the advancement of ZW251, for which an IND submission is now planned for mid-2025,&#8221; Zymeworks said in a statement.
&#8220;As a result, we have paused preparations for the commencement of Phase 1 studies of ZW220 at this time. However, we believe ZW220 remains a highly differentiated, IND-ready ADC with encouraging preclinical data and strong commercial rationale with partnership potential. We look forward to providing future updates on the development for ZW220,&#8221; the company added.
The company plans to initiate a Phase 1 trial for ZW251 this year.
&#8220;ZW251 provides a new therapeutic modality option targeting GPC3 for hepatocellular carcinoma and represents an emerging opportunity in oncology that has yet to be fully realized,&#8221; said Zymeworks Chief Scientific Officer Paul Moore. &#8220;With a potential best-in-class design and differentiated mechanism, we believe our pipeline presents meaningful opportunities for both strategic partnerships and value creation&#8230;&#8221;
In February, Zymeworks achieved a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43967501/zymeworks-announces-achievement-of-14-million-milestone-from-gsk-collaboration" rel="noreferrer noopener">$14 million cash research</a> milestone associated with a clinical milestone from GSK Plc.
In November 2024, the FDA granted accelerated approval to Zymeworks and Jazz Pharmaceuticals Plc partnered Ziihera (zanidatamab) for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">biliary tract cancer</a>.
Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response of 14.9 months. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Price Action: ZYME stock is down 7.97% at $12.13 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44166646/fda-approves-ars-pharmaceuticals-lower-dose-neffy-nasal-spray-for-emergency-allergy-treatment" target="_blank" rel="noreferrer noopener">FDA Approves ARS Pharmaceuticals&#8217; Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment</a></li>
</ul>
Photo via Shutterstock.

Biotech

Earnings

Equities

Health Care

Movers

General

ZYME

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Truist Securities analyst Gregory Fraser maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $220 to $230.

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $185.92, a high estimate of $210.00, and a low estimate of $150.00. Surpassing the previous average price target of $178.75, the current average has increased by 4.01%.
<img src="https://www.benzinga.com/files/images/story/2025/1741204833_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Jazz Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$207.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$179.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Jazz Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Jazz Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Breaking Down Jazz Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.53%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Jazz Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 17.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 1.57%. This signifies efficient management of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.51.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts

On Tuesday, Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) agreed to acquire&nbsp;Chimerix&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) for $8.55 per share in cash, representing a total consideration of <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">approximately $935 million</a>.
Both companies have approved the transaction, and it is expected to close in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44137629/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio" rel="noreferrer noopener">second quarter of 2025</a>.
Chimerix&#8217;s lead clinical asset is dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare brain tumor most commonly affecting children and young adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42112017/fda-approves-jazz-pharmaceuticals-biliary-tract-cancer-drug-making-it-first-commercial-drug-for-its-partner-zymework" rel="noreferrer noopener">FDA Greenlights Jazz Pharma&#8217;s Cancer Drug, A Milestone For Zymework</a>
In February, the FDA accepted Chimerix&#8217;s New Drug Application, seeking accelerated approval for dordaviprone, as a treatment for patients with recurrent H3 K27M-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43776943/chimerix-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-dordaviprone-as-" rel="noreferrer noopener">mutant diffuse glioma</a>.
The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2025. The FDA does not currently plan to hold an advisory committee meeting to discuss the application.
Separately, dordaviprone is being studied in the ongoing Phase 3 ACTION trial, evaluating its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment.
The companies say it is a strategic fit to strengthen Jazz&#8217;s presence in the rare oncology space.
Price Action: CMRX is up 69.7% at $8.415, and JAZZ stock is up 0.33% at $139.40 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44137694/nebius-announces-300-mw-data-center-in-new-jersey-adds-ai-capacity-in-kansas-city-and-iceland" target="_blank" rel="noreferrer noopener">Nebius Announces 300 MW Data Center In New Jersey, Adds AI Capacity In Kansas City And Iceland</a></li>
</ul>
Image: Shutterstock

CMRX

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

Jazz Pharmaceuticals To Acquire Chimerix For Total Cash Consideration Of $935M, Or $8.55/Share

Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and raises the price target from $190 to $200.

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $200

Cantor Fitzgerald analyst Charles Duncan downgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Overweight to Neutral and raises the price target from $140 to $150.

Downgrades

Cantor Fitzgerald Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $150

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>UBS cut Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $83 to $80. UBS analyst Kevin Caliendo maintained a Neutral rating. Henry Schein shares closed at $75.82 on Tuesday. See how other <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $94 to $110. Piper Sandler analyst Yasmeen Rahimi maintained an Overweight rating. Prothena shares closed at $14.63 on Tuesday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity increased ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $14 to $15. Canaccord Genuity analyst David Hynes maintained a Buy rating. ZoomInfo shares closed at $9.53 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut the price target for ZipRecruiter, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) from $9 to $8. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. ZipRecruiter shares closed at $6.73 on Tuesday. <a href="https://www.benzinga.com/quote/ZIP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from $3 to $3.5. RBC Capital analyst Sean Dodge maintained an Outperform rating. agilon health shares closed at $3.63 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/AGL/analyst-ratings">view this stock</a>.</li>
<li>Roth MKM cut Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $5 to $4.5. Roth MKM analyst Philip Shen maintained a Neutral rating. Shoals Technologies Sports shares settled at $4.2650 on Tuesday. <a href="https://www.benzinga.com/quote/SHLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) price target from $65 to $60. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Maplebear Brands shares closed at $48.78 on Tuesday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $220 to $230. Mizuho analyst Gregg Moskowitz maintained a Neutral rating. Check Point Software shares closed at $218.63 on Tuesday.  <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from $200 to $209. JP Morgan analyst Jessica Fye maintained an Overweight rating. Jazz Pharmaceuticals shares settled at $139.67 on Tuesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $396 to $450. UBS analyst Roger Boyd maintained a Buy rating. CrowdStrike shares closed at $379.75 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Markets

CART

CHKP

CRWD

HSIC

PRTA

SHLS

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Watching Jazz Pharmaceuticals; Shares See Volume To The Downside After Cantor Issues Note; Downgraded The Stock To Neutral

WIIM

Jazz Pharmaceuticals shares are trading higher after JP Morgan, Piper Sandler, and Needham raised their respective price targets on the stock.

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and raises the price target from $163 to $176.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $176

Press Releases

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Notizie

Ultime notizie per Jazz Pharmaceuticals (NASDAQ:JAZZ) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO